Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Liver cancer

Core 1 synthase glycoprotein-N-acetylgalactosamine 3-b-galactosyltransferase 1 (C1GALT1)

Human tissue and mouse studies suggest inhibiting C1GALT1 could help treat hepatocellular carcinoma (HCC). In patient samples, C1GALT1 was higher in HCC tissues than in adjacent normal tissues. In HCC patients, high C1GALT expression in tumor tissue was associated with more advanced tumor stage, increased metastasis and decreased survival compared with low C1GALT expression. In a mouse xenograft model of human HCC, small hairpin RNA−mediated knockdown of C1GALT1 decreased tumor growth compared with control shRNA. Next steps could include developing and evaluating pharmacological inhibitors of C1GALT1.

SciBX 6(31); doi:10.1038/scibx.2013.822
Published online Aug. 15, 2013

Patent and licensing status unavailable

Wu, Y.-M. et al. Cancer Res.; published online July 5, 2013;
doi:10.1158/0008-5472.CAN-13-0869
Contact: Min-Chuan Huang, National Taiwan University College of Medicine, Taipei, Taiwan
e-mail:

mchuang@ntu.edu.tw